Hologic revenue to rise in from higher non-COVID diagnostic volume, says Argus

Argus keeps a Buy rating and $89 price target on Hologic while raising the firm’s FY24 EPS view on the stock to $4.17 from $4.15. The higher non-COVID diagnostic volume and higher elective procedural volume should drive revenue growth in FY24, the analyst tells investors in a research note, also calling for increased contributions from recent acquisitions.